{
    "clinical_study": {
        "@rank": "51880", 
        "arm_group": [
            {
                "arm_group_label": "DA-3002", 
                "arm_group_type": "Experimental", 
                "description": "0.14 IU (0.045-0.050mg)/kg/day of DA-3002 is injected for 52 weeks by changing injecting areas"
            }, 
            {
                "arm_group_label": "Genotropin\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "0.14 IU (0.045-0.050mg)/kg/day of Genotropin is injected for 52 weeks by changing injecting areas"
            }
        ], 
        "brief_summary": {
            "textblock": "A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin\u00ae."
        }, 
        "brief_title": "A Clinical Study to Assess the Efficacy and Safety of DA-3002", 
        "condition": "Turner's Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Turner Syndrome", 
                "Gonadal Dysgenesis", 
                "Primary Ovarian Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with Turner's Syndrome through chromosome analysis\n\n          -  The chronological age: 2\u2264AGE\u226412\n\n          -  The yearly growth rate should be less than 6cm; the bone age should be equal or less\n             than 12; the height \u2264 10th percentile for the heights of their agemates\n\n          -  Before the adolescence, Tuner stage I (breast)\n\n          -  Normal thyroid function\n\n        Exclusion Criteria:\n\n          -  Growth hormone was administered for 12 months or longer in the past\n\n          -  Treated with estrogen or adrenal androgens for 12 months or longer in the past\n\n          -  Malignancy, CNS Trauma, Psychiatric Disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813630", 
            "org_study_id": "DA3002_TS_III (Version 1.2)"
        }, 
        "intervention": [
            {
                "arm_group_label": "DA-3002", 
                "intervention_name": "DA-3002", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Genotropin\u00ae", 
                "intervention_name": "Genotropin\u00ae", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Turner's Syndrome", 
            "Short Stature", 
            "Dwarfism"
        ], 
        "lastchanged_date": "August 12, 2013", 
        "location": {
            "contact": {
                "last_name": "Jin Dong Kyu, M.D., Ph.D.", 
                "phone": "82-2-1599-3114"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Patients With Turner's Syndrome", 
        "other_outcome": {
            "measure": "The change of antibodies to growth hormone", 
            "safety_issue": "Yes", 
            "time_frame": "52 weeks"
        }, 
        "overall_contact": {
            "last_name": "Dong Kyu Jin, M.D., Ph.D.", 
            "phone": "82-2-1599-3114"
        }, 
        "overall_official": [
            {
                "affiliation": "Asan Medical Center", 
                "last_name": "Han Wook Yoo, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul St. Mary's Hospital, The Catholic University of Korea", 
                "last_name": "Byung Kyu Suh, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kyungpook National University", 
                "last_name": "Cheol Woo Ko, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Korea University Anam Hospital", 
                "last_name": "Kee Hyoung Lee, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul Medical Center", 
                "last_name": "Dong Kyu Jin, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul National University Hospital", 
                "last_name": "Choong Ho Shin, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Aju University Hospital", 
                "last_name": "Jin Soon Hwang, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Severance Children's Hospital Yonsei University", 
                "last_name": "Ho Seong Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Pusan University Hospital", 
                "last_name": "Woo Young Jeong, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chonnam National University Hospital", 
                "last_name": "Chang Jong Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chungbuk National University", 
                "last_name": "Heon Suk Han, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "A comparison of annualized height velocity between the DA-3002 treated group and the Genotropin\u00ae treated group after 52 weeks", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813630"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "A difference of Height Standard Deviation Score between the DA treated group and the Genotropin\u00ae treated group after 52 weeks", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}